VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.

Exclusion Criteria

• •Criteria for exclusion from participation in this study are presented below.
• •1. Pregnancy or lactation
• •2. Body mass index at screening \<18 or \>30 kg/m2
• •3. Clinically significant intestinal adhesions and/or chronic abdominal pain that can interfere with the conduct of the study
• •4. Active Crohn's disease or IBD (as evaluated by standard procedures employed by the investigator/institution). If in remission, must be ≥12 weeks of remission prior to screening
• •5. Inflammatory bowel disease patients who have NOT been on a stable drug treatment regimen for at least the past 3 months prior to screening
• •6. Visible blood in the stool within the last 3 months
• •7. Known heart failure or active coronary disease
• •8. Alcohol or drug abuse within the last 12 months by history, or a disqualifying positive urine drug test at screening.
• •9. Inadequate renal function as defined by serum creatinine \<0.7 or \>1.3 mg/dL (in men) and \<0.6 or \>1.1 mg/dL in women.
• •10. Personal or family history of medullary thyroid cancer.
• •11. History of pancreatitis
• •12. Any use of growth hormone, or growth factors such as native GLP-2 or GLP-2 analog (teduglutide) within the last 3 months
• •13. Use of antibiotics within the last 30 days
• •14. Patient not capable of understanding or not willing to adhere to the study visit schedules and other protocol requirements